Tucker Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tucker Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,754	Closed	-$189K	–	1385
2023 Q2	$189K	Buy	8,754 +5,129	+141%	+$139K	0.05%	110
2023 Q1	$106K	Buy	+3,625	New	+$126K	0.03%	141

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Tucker Asset Management's AMLX Position: Q3 2023 in Review

Tucker Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 8,754 shares — an estimated $189K sold.

Tucker Asset Management first reported a position in AMLX in Q1 2023 and held it in 2 quarters. The position peaked at $189K in Q2 2023. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

Tucker Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Tucker Asset Management sold 8,754 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $189K.
Tucker Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 2 quarters.
Tucker Asset Management's Amylyx Pharmaceuticals position peaked at $189K in Q2 2023.
170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.